ForwardLooking Statements This press release contains forwardlooking statements about the business prospects of BioMarin Pharmaceutical Inc BioMarin including without limitation statements about the potential benefits and impact of ROCTAVIAN for treating adults with severe hemophilia A including i the potential for ROCTAVIAN to transform treatment for such patients by providing years of bleed control following a single infusion of ROCTAVIAN and ii allowing such patients to produce their own FVIII and thereby limit bleeding episodes the clinical development of ROCTAVIAN including i BioMarins continued monitoring of the longterm effects of treatment with an extension study as well as postapproval studies and the duration of such monitoring and ii clinical studies regarding potential product expansion opportunities for ROCTAVIAN the commercialization of ROCTAVIAN including i BioMarins ability to manufacture sufficient ROCTAVIAN to meet commercial demand throughout the products lifecycle ii BioMarins plans to immediately educate physicians and patients about ROCTAVIAN iii BioMarins goal to ensure that every eligible adult interested in ROCTAVIAN is able to receive treatment iv BioMarins plans to offer outcomesbased warranties for ROCTAVIAN to all US insurers and v BioMarins goal that HTCs are prepared to administer ROCTAVIAN the expectation that ROCTAVIAN will offer significant savings to society the expectation that BioMarins outcomesbased warranties will further enhance the value of ROCTAVIAN to payers and BioMarins expectations regarding the number of adult patients with severe hemophilia in the US who will be eligible to receive ROCTAVIAN with the initial FDA approval